Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness

The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.A clinical trial participant receiving an infusion of an anti-amyloid Alzheimer’s drug in New York last year.